Clopidogrel: The Future Choice for Preventing Platelet Activation During Coronary Stenting?

Author： Gurbel P.A.   O'connor C.M.   Cummings C.C.   Serebruany V.L.  

Publisher： Academic Press

ISSN： 1043-6618

Source： Pharmacological Research, Vol.40, Iss.2, 1999-08, pp. : 107-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clopidogrel an alternative to ticlopidine in coronary stenting

By  

Inpharma, Vol. 1, Iss. 1223, 2000-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Clopidogrel Resistance: Implications for Coronary Stenting

By  

Current Pharmaceutical Design, Vol. 12, Iss. 10, 2006-04 ,pp. : 1261-1269

Bentham Science Publishers

Access to resources Recommend Favorite

Clopidogrel + eptifibatide CLEARs PLATELETS after coronary stenting

By  

Inpharma, Vol. 1, Iss. 1480-1481, 2005-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Clopidogrel vs ticlopidine: tolerability after coronary stenting

By  

Inpharma, Vol. 1, Iss. 1436, 2004-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

A polymorphism in the cytochrome P450 3A4 (CYP3A4) gene influences platelet activation and response to clopidogrel in patients with coronary artery disease

By  

Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite